公开(公告)号：US20190351052A1

公开(公告)日：2019-11-21

申请号：US16394270

申请日：2019-04-25

申请人： 7 Hills Pharma LLC ,  Texas Heart Institute

发明人： Darren G. Woodside ,  Peter Vanderslice ,  Upendra K. Marathi

IPC分类号： A61K39/39 ,  A61K31/17 ,  A61K31/36 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/00 ,  A61K31/381 ,  A61K31/165 ,  A61K31/16

摘要： Compositions including one or more antigens and one or more integrin activating compounds capable of adjuvanting the one or more antigens contained and increasing an immune response to the one or more antigen in a vaccine preparation.

公开(公告)号：US10471047B2

公开(公告)日：2019-11-12

申请号：US16033008

申请日：2018-07-11

申请人： STC.UNM

发明人： Eric R. Prossnitz ,  Geetanjali Sharma

IPC分类号： A61K31/436 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/16 ,  A61K31/7088 ,  A61K38/28

摘要： The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).

公开(公告)号：US10456355B1

公开(公告)日：2019-10-29

申请号：US16343163

申请日：2017-10-25

申请人： CROSSJECT

发明人： Pauline Bardonnaud ,  Frédérique Flores-Ivanez

IPC分类号： A61K31/56 ,  A61K31/16 ,  A61K9/00 ,  A61K31/573 ,  A61K31/10 ,  A61K47/20 ,  A61M5/30 ,  A61K47/02 ,  A61K47/18

摘要： A pharmaceutical hydrocortisone solution including at least hydrocortisone or a pharmaceutically-acceptable salt thereof, rongalite, disodium EDTA, and a solvent. Also relates to its use in the treatment of acute adrenal insufficiency and asthma. Also relates to an injection kit including an injection device and this pharmaceutical solution.

公开(公告)号：US10441582B2

公开(公告)日：2019-10-15

申请号：US15498212

申请日：2017-04-26

申请人： Oh Young Yeo

发明人： Oh Young Yeo

IPC分类号： A61K31/4709 ,  A61K31/16 ,  A61K9/00 ,  A61K31/525 ,  A61K49/04 ,  A61K47/22 ,  A61K9/10 ,  A61K31/167 ,  A61K47/02 ,  A61K31/49

摘要： Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC50 value against MKN-45 cells, which is about 10 times lower than Paclitaxel, as determined by an MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. The anticancer composition can be administered as a safe anticancer agent in clinical applications, and also shows an anticancer effect by inducing the necrosis and detachment of solid cancer cells. Particularly, the anticancer composition has an anticancer mechanism by which the composition acts locally in a tumor tissue administered with the composition and shows a rapid antitumor effect (1-2 weeks after administration).

公开(公告)号：US10441555B2

公开(公告)日：2019-10-15

申请号：US15260554

申请日：2016-09-09

申请人： Olatec Therapeutics LLC

发明人： Joseph P. St. Laurent ,  Gerald S. Jones ,  David M. Bresse

IPC分类号： A61K31/16 ,  A61K31/145 ,  A61K9/00 ,  A61K47/08 ,  A61K47/14 ,  A61K9/06 ,  A61K47/18 ,  A61K47/32

摘要： The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylsulfonyl)alkylamine or ω-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

公开(公告)号：US20190308960A1

公开(公告)日：2019-10-10

申请号：US16190964

申请日：2018-11-14

申请人： Proteostasis Therapeutics, Inc.

发明人： Cecilia M. Bastos ,  Benito Munoz ,  Bradley Tait

IPC分类号： C07D413/12 ,  C07F7/18 ,  C07D413/14 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/16 ,  A61K31/695 ,  A61K45/06 ,  C07C243/36 ,  C07D285/12 ,  C07D261/18 ,  C07D417/12 ,  C07D233/61 ,  C07D231/12 ,  A61K31/42

摘要： The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.

公开(公告)号：US10420736B2

公开(公告)日：2019-09-24

申请号：US15762726

申请日：2016-09-30

申请人： TOHOKU UNIVERSITY

发明人： Toru Nakazawa ,  Takaaki Akaike ,  Hiroshi Kunikata

IPC分类号： A61K31/16 ,  A61K38/00 ,  A61K31/198 ,  A61P27/02 ,  A61K31/4162 ,  A61K45/06 ,  A61P41/00 ,  A61P43/00 ,  A61K9/00 ,  A61K9/08

摘要： The present invention addresses the problem of providing an intraocular irrigating solution that allows the intraocular tissue to be sufficiently protected during ophthalmic surgery and further has high safety. The problem is solved by an intraocular irrigating solution containing at least one of active sulfur molecules of which examples include cysteine persulfide and glutathione persulfide.

公开(公告)号：US10398707B2

公开(公告)日：2019-09-03

申请号：US15722205

申请日：2017-10-02

申请人： Allergan, Inc.

发明人： Patrick M. Hughes

IPC分类号： A61K31/5575 ,  A61K31/16 ,  A61K9/16 ,  A61F9/00 ,  A61K9/00 ,  A61K47/34

摘要： Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

公开(公告)号：US20190233377A1

公开(公告)日：2019-08-01

申请号：US16379487

申请日：2019-04-09

申请人： ZENO ROYALTIES & MILESTONES, LLC

发明人： Kevin Duane Bunker ,  Chuangxing Guo ,  Mark Charles Grier ,  Chad Daniel Hopkins ,  Joseph Robert Pinchman ,  Deborah Helen Slee ,  Peter Qinhua Huang ,  Mehmet Kahraman

IPC分类号： C07D213/89 ,  A61K45/06 ,  C07C317/30 ,  A61K31/13 ,  C07C233/14 ,  C07C233/05 ,  A61K31/444 ,  A61K31/27 ,  A61K31/164 ,  A61K31/16 ,  A61K31/145 ,  C07C211/38 ,  C07C215/42 ,  C07C233/06 ,  C07C233/23 ,  C07C233/13 ,  C07C233/09

CPC分类号： C07D213/89 ,  A61K31/13 ,  A61K31/145 ,  A61K31/16 ,  A61K31/164 ,  A61K31/27 ,  A61K31/444 ,  A61K45/06 ,  C07C211/38 ,  C07C215/42 ,  C07C233/05 ,  C07C233/06 ,  C07C233/09 ,  C07C233/13 ,  C07C233/14 ,  C07C233/23 ,  C07C317/30 ,  C07C2601/02 ,  C07C2602/38 ,  C07C2603/62 ,  A61K2300/00

摘要： Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.

公开(公告)号：US20190231657A1

公开(公告)日：2019-08-01

申请号：US15880764

申请日：2018-01-26

申请人： Chris Gerlach ,  Michael Davies

发明人： Chris Gerlach ,  Michael Davies

IPC分类号： A61K8/04 ,  A61K31/60 ,  A61K47/10 ,  A61K47/38 ,  A61K47/18 ,  A61K31/16 ,  A61Q19/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61K9/06 ,  A61K8/365 ,  A61K8/42 ,  A61K8/86 ,  A61K8/34 ,  A61K8/73

CPC分类号： A61K8/042 ,  A61K8/342 ,  A61K8/365 ,  A61K8/42 ,  A61K8/731 ,  A61K8/86 ,  A61K9/06 ,  A61K31/16 ,  A61K31/60 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38 ,  A61Q5/006 ,  A61Q5/02 ,  A61Q19/007

摘要： A salicylic acid gel contains salicylic acid, a thickener, and a stabilizer compound. The gel may be diluted and/or incorporated into final skin care products.